VANCOUVER, BC – (January 10, 2019) — Breathtec Biomedical Inc. (CSE: BTH) advises that Kulwant Malhi (the “Acquiror”), through a series of securities acquisition transactions in the share capital of Breathtec BioMedical Inc. (the “Issuer”), and immediately after these securities transactions, owns or controls directly and indirectly, an aggregate of 6,851,171 common shares (the “Shares”) of the Issuer, representing approximately 23.886% of the Issuer’s issued and outstanding Shares. The Acquiror acquired the Shares on the public market through the facilities of the Canadian Securities Exchange, by way of an offering by the Issuer and/or by way of a share exchange agreement (the share exchange as more particularly described in the Issuer’s October 22,2018, October 9, 2018 and August 2, 2018 news releases). The Acquiror holds a total of 331,501 Shares directly, a total of 5,647,170 Shares held indirectly through BullRun Capital Inc., a private company over which the Acquiror has control and direction, and a total of 872,500 Shares held indirectly through Cannabix Breathalyzer Inc., a private company over which the Acquiror has control and direction.
The Acquiror also holds a total of 6,407,170 warrants (5,647,170warrants held indirectly through BullRun Capital Inc. and 760,000 warrants held indirectly through Cannabix Breathalyzer Inc.), representing approximately 22.338% of the Issuer’s issued and outstanding Shares.
The Shares of the Issuer are listed on the Canadian Securities Exchange and trade under the trading symbol “BTH.“ The Shares were acquired for investment purposes. Depending on market conditions, the Acquiror may in the future increase or decrease his investment in the Issuer.
An Early Warning Report respecting the security acquisition transactions has been filed on SEDAR under the Issuer’s profile and can beviewed at www.sedar.com.
(Signed) Kulwant Malhi
c/o Suite 915, 700 W Pender St Vancouver BC V6C 1G8